• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

    5/12/22 1:00:00 PM ET
    $AERC
    $NVCR
    $PODD
    $RNLX
    Environmental Services
    Utilities
    Medical/Dental Instruments
    Health Care
    Get the next $AERC alert in real time by email

    PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee.

    Mr. Scannell brings over 30 years of experience and success delivering market-leading results from his leadership roles at Stryker Corporation (NYSE:SYK) ("Stryker"), one of the world's leading medical technology companies. Mr. Scannell served as President and Chief Operating Officer of Stryker between 2018 and 2021, overseeing all of Stryker's commercial businesses and regions globally. Prior to this, he served as group president for Stryker's MedSurg & Neurotechnology businesses for ten years. Mr. Scannell currently serves as a director and non-executive chairman of the Board of Directors for Insulet Corporation (NASDAQ:PODD) and is a director on the boards of Novocure Limited (NASDAQ:NVCR), Renalytix plc (NASDAQ:RNLX) and Collagen Matrix, Inc.

    "Tim Scannell is a medical technology industry veteran with vast experience and a tremendous track record of success. He drove market leading sales and supported Stryker's top tier M&A results during his time at Stryker. He will be a great addition to our Board," said Jason DiBona, AeroClean's Chief Executive Officer. "Tim's interest in joining our Board and helping advance our mission is a testament to our Company's vision. I welcome Tim to the team and look forward to his contributions to the success of AeroClean."

    "I am proud to join the Board of AeroClean. I look forward to supporting and advancing AeroClean's mission of keeping life going with healthy, safe air solutions," said Mr. Scannell. "I am energized by AeroClean's mission, impressed by their board and management team, and enthusiastic about the Company's opportunity to build a great business with tremendous impact on millions of lives in the years to come."

    About AeroClean Technologies

    AeroClean is a pathogen elimination technology company on a mission to keep work, play and life going—with continuous air sanitization products called Pūrgo™ (pure-go). We create solutions for hospitals, offices, and many shared spaces as well as elevators and more. Pūrgo™ products feature SteriDuct™, a proprietary technology developed by our best-in-class aerospace engineers, medical scientists and innovators. Powered by SteriDuct™, our solutions are medical grade, eradicating viral, fungal and bacterial airborne pathogens. Our purpose is simple: to never stop innovating solutions that keep people healthy and safe, so life never stops. Learn more at aeroclean.com.

    Media Contact

    Drew Tybus

    drew@oakpr.com

    Investor Relations Contacts

    Ryan Tyler

    Chief Financial Officer, AeroClean

    RTyler@AeroClean.com

    Brian Pinkston

    MATTIO Communications

    aeroclean@mattio.com



    Primary Logo

    Get the next $AERC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AERC
    $NVCR
    $PODD
    $RNLX

    CompanyDatePrice TargetRatingAnalyst
    Insulet Corporation
    $PODD
    5/20/2026Outperform
    William Blair
    Insulet Corporation
    $PODD
    4/24/2026$220.00Buy → Neutral
    Rothschild & Co Redburn
    Stryker Corporation
    $SYK
    4/13/2026$410.00Outperform
    Leerink Partners
    Insulet Corporation
    $PODD
    4/7/2026$230.00Buy → Neutral
    Citigroup
    Stryker Corporation
    $SYK
    2/20/2026Outperform
    William Blair
    Stryker Corporation
    $SYK
    1/27/2026$387.00Hold
    TD Cowen
    Insulet Corporation
    $PODD
    1/27/2026$294.00Hold
    TD Cowen
    Insulet Corporation
    $PODD
    1/12/2026$274.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $AERC
    $NVCR
    $PODD
    $RNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stonesifer Timothy C. bought $400,393 worth of shares (2,790 units at $143.51), increasing direct ownership by 45% to 9,041 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/4/26 4:25:37 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Weatherman Elizabeth H bought $497,490 worth of shares (3,450 units at $144.20), increasing direct ownership by 50% to 10,352 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/3/26 4:19:18 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Minogue Michael R bought $499,847 worth of shares (2,030 units at $246.23) (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/26/26 7:05:23 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

    Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans. "At Insulet, we believe

    6/4/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

    Enhanced algorithm with new 100 mg/dL Target Glucose and improved alarm handling helps users improve time in range and stay in Automated Mode longer Omnipod 5 is now compatible with Abbott's Libre 3 Plus sensor in U.S., giving users more choice in how they manage their diabetes New features are designed to improve outcomes, reduce diabetes burden, and unlock barriers to AID technology to meet the needs of people with diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery

    6/3/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures

    PORTAGE, Mich., June 2, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its TPX HD, a premium small bone power tool designed to support performance, control and ergonomics in a wide range of challenging orthopaedic procedures such as total joint revisions, minimally invasive surgery and oral maxillofacial procedures. "Revision procedures are some of the most demanding cases surgeons face, especially when metal cutting is involved," said Mike Carlin, president of Stryker's Ortho Tech division. "TPX HD was designed with tho

    6/2/26 9:03:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    SEC Filings

    View All

    SEC Form SD filed by Insulet Corporation

    SD - INSULET CORP (0001145197) (Filer)

    5/28/26 4:05:39 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    5/26/26 4:06:27 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Stryker Corporation

    SD - STRYKER CORP (0000310764) (Filer)

    5/22/26 10:27:54 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair resumed coverage on Insulet

    William Blair resumed coverage of Insulet with a rating of Outperform

    5/20/26 8:53:26 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Insulet from Buy to Neutral and set a new price target of $220.00

    4/24/26 8:03:49 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Leerink Partners initiated coverage on Stryker with a new price target

    Leerink Partners initiated coverage of Stryker with a rating of Outperform and set a new price target of $410.00

    4/13/26 9:01:23 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stonesifer Timothy C. bought $400,393 worth of shares (2,790 units at $143.51), increasing direct ownership by 45% to 9,041 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/4/26 4:25:37 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Borio Luciana sold $59,887 worth of shares (418 units at $143.27), decreasing direct ownership by 9% to 4,329 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/4/26 4:23:25 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Leung Gabriel sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 3% to 89,499 units (SEC Form 4) to satisfy withholding tax

    4 - NovoCure Ltd (0001645113) (Issuer)

    6/3/26 4:54:07 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Financials

    Live finance-specific insights

    View All

    Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio

    Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease. "This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease," said Kevin Lobo, Chair and CEO, Stryker. "By integrating AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources, we are well-positioned to deliver solutions that support p

    5/7/26 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker declares an $0.88 per share quarterly dividend

    Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 m

    5/7/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Insulet Reports First Quarter 2026 Results

    Raises Full Year Total Company Revenue Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company's guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4 million, rose 36.9%, or 33.0% in constant currency U.S. Omnipod revenue of $515.6 million, increased 28.3% International Omnipod revenue of $242.9 million, increased 59.4

    5/6/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    10/7/24 11:37:08 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Renalytix plc

    SC 13D/A - Renalytix plc (0001811115) (Subject)

    10/2/24 8:05:02 PM ET
    $RNLX
    Medical Specialities
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet Appoints Mike Panos as Chief Commercial Officer

    Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet's global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330524787/en/ "We have a significant growth opportunity in front of us, driven by strong clinical outcomes

    3/30/26 8:30:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    Stryker showcases continued innovation across orthopaedics at AAOS 2026 Annual Meeting

    Evolving technologies and offerings reinforce commitment to shaping the future of orthopaedic care PORTAGE, Mich., March 3, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases its commitment to innovation across orthopaedic specialties with the introduction of the newest additions to the Triathlon® Total Knee System, the expanded Mako SmartRobotics™ portfolio and continued evolution of the power tool portfolio at the American Academy of Orthopaedic Surgeons' (AAOS) 2026 Annual Meeting in New Orleans. Triathlon Gold: Building on the legacy

    3/3/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care